Vaxart Board Battle Intensifies as Independent Directors Urge Shareholders to Back All Six Nominees Ahead of July 16 Annual Meeting
核心洞察
Vaxart's two newest independent directors, James Breitmeyer and Kevin Finney, sent a letter to shareholders urging votes for all six board nominees on the WHITE proxy card ahead of the July 16, 2026 Annual Meeting.
The letter emphasizes that the dissident shareholder nominees lack relevant biotechnology, public company leadership, or vaccine regulatory experience, and their election would be "value destructive."
Vaxart is advancing a BARDA (搜索)-funded Phase 2b COVID-19 (搜索) oral vaccine trial comparing its pill candidate against an approved mRNA injectable, with near-term safety and immunogenicity data expected from a 400-participant Sentinel Cohort.
Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines, is facing a pivotal shareholder vote at its upcoming Annual Meeting of Stockholders scheduled for July 16, 2026. The company's two newest independent directors — James B. Breitmeyer, M.D., Ph.D., and Kevin P. Finney — have issued a letter to shareholders urging them to vote "FOR" all six of the company's director nominees on the WHITE proxy card, framing the election as critical to the company's future at a time of significant clinical momentum.
The letter, mailed June 16, 2026, represents the latest salvo in a proxy contest where a group of dissident shareholders is seeking to replace half of Vaxart's board with their own nominees. Breitmeyer and Finney, who each joined the board within the last 18 months, emphasized their combined 70-plus years of biotechnology experience spanning clinical development, regulatory strategy, financing, and executive leadership.
"We joined the Board with the explicit purpose of providing fresh perspectives and open minds," the directors wrote. "We did not come to this Boardroom with preconceived notions or established relationships with Vaxart's other directors."
Clinical Pipeline at a Critical Juncture
Vaxart's proprietary oral vaccine platform, known as VAAST, is designed to deliver recombinant vaccines via pills that can be stored and shipped without refrigeration, eliminating needle-stick injury risks. The company's pipeline includes programs targeting coronavirus, norovirus (搜索), seasonal and avian influenza (搜索), and a therapeutic vaccine for human papillomavirus (搜索) (HPV).
The lead program is a BARDA (搜索)-funded Phase 2b COVID-19 (搜索) trial that directly compares Vaxart's oral pill vaccine candidate against an approved mRNA injectable. The trial includes a Sentinel Cohort of approximately 400 participants, with topline 12-month safety and immunogenicity data expected in the near term, and a Main Cohort — a double-blinded study of approximately 5,000 participants — with a full efficacy and safety readout anticipated in the mid term.
Positive Phase 2b results would trigger an option for strategic partner Dynavax (搜索), now part of Sanofi, to further develop and commercialize the asset. The partnership extended Vaxart's cash runway into the second quarter of 2027.
In the norovirus (搜索) program, Vaxart is building on prior Phase 2 challenge data that demonstrated potential to reduce infection, illness, and viral shedding. The company is currently evaluating cross-reactivity of its second-generation bivalent candidate, which has shown significantly higher antibody responses compared to first-generation constructs. A Phase 2b safety and immunogenicity study is planned for the near term, subject to securing additional partnership or external funding.
Financial Discipline and Operational Streamlining
The board letter highlights several measures taken to preserve capital and extend the company's runway. In April 2026, Vaxart entered into a $25 million share purchase agreement with Lincoln Park Capital (搜索), providing flexible financing if additional capital is needed. The company also implemented a 21% workforce reduction in 2025 and completed the relocation of its corporate headquarters to reduce fixed overhead.
These actions followed stop-work orders issued by BARDA (搜索) in early 2025 that affected vaccine programs across multiple companies. CEO Steven Lo, who assumed the role a little more than two years ago, helped secure the continuation of BARDA funding for the lead COVID-19 (搜索) program and led the negotiation of the Dynavax (搜索) strategic partnership.
"These were consequential actions taken to preserve Vaxart's opportunity to operate," Breitmeyer and Finney stated. "In our view, they demonstrate the kind of oversight and action Vaxart needs: engaged, pragmatic and made possible because of the specific experience and expertise our Board and management team bring to the table."
Contrasting Board Credentials
The company has drawn sharp distinctions between its nominees and those put forward by the dissident shareholder group. According to Vaxart, the dissident nominees have backgrounds principally in insurance, medical practice, and small business operations, with none having served as a director or senior executive of a public company or clinical-stage vaccine company.
The company's slate includes: Steven Lo, CEO, whose compensation is more than 60% equity-based with multi-year vesting and who has never sold a single share of company stock; Dr. Elaine J. Heron, former CEO and Chair of Amplyx Pharmaceuticals (acquired by Pfizer) and a former board member of BioMarin Pharmaceutical; and Dr. David Wheadon, former Senior Vice President of Global Regulatory Affairs at AstraZeneca Pharmaceuticals and a former director of Karuna Therapeutics (acquired by Bristol Myers Squibb for approximately $14 billion).
"Removing these directors and replacing them with unqualified nominees would immediately undermine the Company's ability to bring informed, experienced judgment to the decisions that matter most for Vaxart's future," the independent directors warned.
The average tenure of all six nominees is 2.3 years, with two directors having joined within the last year — a point the company emphasizes as evidence of board refreshment and responsiveness to shareholder feedback.
Looking Toward the July 16 Vote
The Annual Meeting of Stockholders is scheduled for July 16, 2026. Vaxart has retained Campaign Management, LLC as its proxy solicitor and has established Vote.Vaxart.com as a resource for shareholders. The company's definitive proxy statement and related materials have been filed with the U.S. Securities and Exchange Commission.
"Vaxart is on the brink of unlocking the value of years of scientific innovation," Breitmeyer and Finney concluded. "But there is much more work that needs to be done. This is not the time to disrupt a Board that has the experience, independence and judgment to oversee the path forward."